Genmab — Februar 2019
-
Og der har været sagt adskillige ting herinde om de 2 salgsmilestones, nogle ukorrekte. Det står i outlook, at de forventer ialt 1500 mioDKK (ialt, ved 2,5- og 3-milestones), og David sagde senere i samme svar: "..particularly the $3 billion-related milestone, $150 million, DKK 900 million".
-
Fra Børsen - citat: Med den nuværende behandlingstid kan man behandle omkring to patienter om dagen per stol, men det vil ændre sig til fire per time inklusive en kop kaffe med den subkutane version. Og det vil, tror jeg, dramatisk booste brugen af Darzalex
-
Uanset, så hvade David en exellent pointe: "..and I think we saw in 2018, we didn't have any movement of our guidance overall. And of course, look, I've been very transparent with the milestones that are in there. They're binary. And look, for the long-term trajectory, our DARZALEX sales, whether they're 2.99 billion in 2019 or 3.01 billion in 2019 makes absolutely no difference of where the future success of DARZALEX will be.."!
-
Forventes SC versionen at være på markedet allerede i starten af 2020?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind